Logiq, Inc. Acquires EVIMATE, Heralding a New Era in Medical Device Innovation
Logiq, Inc. (OTC PINK:LGIQ) has announced a definitive agreement to acquire EVIMATE, a medical device innovation company, for $5 million. This acquisition marks Logiq's entry into the medical device sector. EVIMATE specializes in advanced vital sign monitoring products that utilize AI technology for comprehensive health metric tracking and predictive analytics.
EVIMATE's solution includes next-generation devices and a user-friendly app that continuously monitors key health indicators such as temperature, heart rate, ECG, blood pressure, oxygen levels, and glucose levels. The system is designed for Remote Patient Monitoring (RPM), providing real-time insights and alerts to healthcare providers, caregivers, and family members.
Additionally, EVIMATE has developed an automotive healthcare system for monitoring driver vitals, featuring sensors in the driver's seat and steering wheel to collect vital signs like heart functions, respiratory rate, stress level, and blood oxygen level. All devices mentioned will require FDA regulatory approvals and additional patent filings for IP protection.
Logiq, Inc. (OTC PINK:LGIQ) ha annunciato un accordo definitivo per acquisire EVIMATE, un'azienda innovativa nel campo dei dispositivi medici, per 5 milioni di dollari. Questa acquisizione rappresenta l'ingresso di Logiq nel settore dei dispositivi medici. EVIMATE è specializzata in prodotti avanzati per il monitoraggio dei segni vitali che utilizzano la tecnologia AI per un tracciamento completo dei metriche sanitarie e analisi predittive.
La soluzione di EVIMATE include dispositivi di nuova generazione e un'app user-friendly che monitora continuamente indicatori chiave della salute come temperatura, frequenza cardiaca, ECG, pressione sanguigna, livelli di ossigeno e livelli di glucosio. Il sistema è progettato per il Monitoraggio Remoto dei Pazienti (RPM), fornendo informazioni in tempo reale e avvisi a fornitori di assistenza sanitaria, caregiver e familiari.
Inoltre, EVIMATE ha sviluppato un sistema sanitario per veicoli per monitorare i segni vitali del conducente, dotato di sensori nel sedile del conducente e nel volante per raccogliere segni vitali come le funzioni cardiache, la frequenza respiratoria, il livello di stress e il livello di ossigeno nel sangue. Tutti i dispositivi menzionati richiederanno approvazioni regolatorie dalla FDA e ulteriori registrazioni di brevetti per la protezione della proprietà intellettuale.
Logiq, Inc. (OTC PINK:LGIQ) ha anunciado un acuerdo definitivo para adquirir EVIMATE, una empresa innovadora en dispositivos médicos, por 5 millones de dólares. Esta adquisición marca la entrada de Logiq en el sector de dispositivos médicos. EVIMATE se especializa en productos avanzados para la monitorización de signos vitales que utilizan tecnología de IA para el seguimiento integral de métricas de salud y análisis predictivos.
La solución de EVIMATE incluye dispositivos de próxima generación y una aplicación fácil de usar que monitorea continuamente indicadores clave de salud como temperatura, frecuencia cardíaca, ECG, presión arterial, niveles de oxígeno y niveles de glucosa. El sistema está diseñado para el Monitoreo Remoto de Pacientes (RPM), proporcionando información en tiempo real y alertas a proveedores de salud, cuidadores y familiares.
Además, EVIMATE ha desarrollado un sistema de atención médica automotriz para monitorear los signos vitales del conductor, que cuenta con sensores en el asiento del conductor y el volante para recopilar signos vitales como las funciones cardíacas, frecuencia respiratoria, nivel de estrés y nivel de oxígeno en sangre. Todos los dispositivos mencionados requerirán aprobaciones regulatorias de la FDA y presentaciones adicionales de patentes para la protección de la propiedad intelectual.
Logiq, Inc. (OTC PINK:LGIQ)는 EVIMATE라는 의료 기기 혁신 회사와 500만 달러에 대한 확정 계약을 체결했다고 발표했습니다. 이번 인수는 Logiq의 의료 기기 분야 진출을 의미합니다. EVIMATE는 AI 기술을 활용하여 포괄적인 건강 지표 추적 및 예측 분석을 제공하는 고급 생체 신호 모니터링 제품을 전문으로 하고 있습니다.
EVIMATE의 솔루션은 차세대 장치와 사용하기 쉬운 앱을 포함하여 온도, 심박수, ECG, 혈압, 산소 수준 및 포도당 수준과 같은 주요 건강 지표를 지속적으로 모니터링합니다. 이 시스템은 원격 환자 모니터링(RPM)을 위해 설계되었으며, 의료 제공자, 간병인 및 가족에게 실시간 통찰력과 경고를 제공합니다.
또한, EVIMATE는 운전자의 생체 신호를 모니터링하기 위한 자동화된 헬스케어 시스템을 개발하여 운전자의 좌석과 스티어링 휠에 센서를 배치하여 심장 기능, 호흡 속도, 스트레스 수준 및 혈중 산소 수준과 같은 생체 신호를 수집합니다. 언급된 모든 장치에는 FDA 규제 승인 및 지적 재산 보호를 위한 추가 특허 출원이 필요합니다.
Logiq, Inc. (OTC PINK:LGIQ) a annoncé un accord définitif pour acquérir EVIMATE, une entreprise d'innovation en dispositifs médicaux, pour 5 millions de dollars. Cette acquisition marque l'entrée de Logiq dans le secteur des dispositifs médicaux. EVIMATE se spécialise dans les produits avancés de surveillance des signes vitaux qui utilisent la technologie AI pour un suivi complet des indicateurs de santé et une analyse prédictive.
La solution d'EVIMATE comprend des dispositifs de nouvelle génération et une application conviviale qui surveille en permanence des indicateurs de santé clés tels que la température, le rythme cardiaque, l'ECG, la pression artérielle, les niveaux d'oxygène et les niveaux de glucose. Le système est conçu pour la Surveillance à Distance des Patients (RPM), fournissant des informations en temps réel et des alertes aux professionnels de la santé, aux aidants et aux membres de la famille.
De plus, EVIMATE a développé un système de santé automobile pour surveiller les signes vitaux du conducteur, doté de capteurs dans le siège du conducteur et le volant pour collecter des signes vitaux tels que les fonctions cardiaques, le rythme respiratoire, le niveau de stress et le niveau d'oxygène dans le sang. Tous les dispositifs mentionnés nécessiteront des approbations réglementaires de la FDA et des dépôts de brevets supplémentaires pour la protection de la propriété intellectuelle.
Logiq, Inc. (OTC PINK:LGIQ) hat eine endgültige Vereinbarung zur Übernahme von EVIMATE, einem innovativen Unternehmen im Bereich medizinische Geräte, für 5 Millionen Dollar bekannt gegeben. Diese Übernahme markiert Logiqs Einstieg in den Sektor der medizinischen Geräte. EVIMATE ist auf hochwertige Produkte zur Überwachung von Vitalzeichen spezialisiert, die KI-Technologie für eine umfassende Gesundheitsmetrikenverfolgung und prädiktive Analytik nutzen.
Die Lösung von EVIMATE umfasst Geräte der nächsten Generation und eine benutzerfreundliche App, die kontinuierlich wichtige Gesundheitsindikatoren wie Temperatur, Herzfrequenz, EKG, Blutdruck, Sauerstoffgehalt und Glukosespiegel überwacht. Das System ist für Remote Patient Monitoring (RPM) ausgelegt und bietet Echtzeit-Einblicke und Warnungen für Gesundheitsdienstleister, Pflegekräfte und Familienmitglieder.
Darüber hinaus hat EVIMATE ein automobilmedizinisches System entwickelt, um die Vitalzeichen des Fahrers zu überwachen, mit Sensoren im Fahrersitz und im Lenkrad zur Erfassung von Vitalzeichen wie Herzfunktionen, Atemfrequenz, Stresslevel und Blut-Sauerstoffgehalt. Alle genannten Geräte benötigen FDA-Regulierungszulassungen und zusätzliche Patentierungen zum Schutz des geistigen Eigentums.
- Acquisition of EVIMATE for $5 million, diversifying Logiq's portfolio into medical devices
- EVIMATE's advanced AI-powered vital sign monitoring products offer comprehensive health tracking
- Remote Patient Monitoring (RPM) capabilities provide real-time insights and alerts
- Innovative automotive healthcare system for monitoring driver vitals
- FDA regulatory approvals required for all devices mentioned
- Additional patent filings needed for IP protection
- Potential integration challenges and costs associated with the acquisition
EVIMATE in Healthcare: The Logiq of Innovation
Logiq, Inc. Acquires EVIMATE, Heralding a New Era in Medical Device Innovation
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Logiq, Inc. (OTC PINK:LGIQ) ("Logiq" or "the Company") proudly announces the definitive agreement to acquire EVIMATE ("EVIMATE"), a pioneer in medical device innovation. This acquisition, valued at
EVIMATE: Efficient in Hospitals, Comfortable at Home and Driver Seat
EVIMATE's cutting-edge suite of vital sign products leverage advanced AI technology to provide comprehensive monitoring and predictive analytics across key health metrics. The solution combines next-generation devices with a user-friendly app to ensure continuous, accurate monitoring of temperature, heart rate, ECG, blood pressure, oxygen levels, and glucose levels. Designed to meet Remote Patient Monitoring (RPM) standards, it offers real-time insights and alerts to healthcare providers, caregivers, and family members, enhancing patient safety and care. In addition, EVIMATE developed advanced automotive healthcare system to monitor driver/ pilot vitals. Among many contactless systems provided by EVIMATE the set of fifteen preinstalled sensors in driver's seat assisted by nine steering embedded wheel mounted sensors, help to collect additional vital signs like monitoring the heart functions, HR, HRV, respiratory rate, stress level, blood oxygen level (steering wheel add-on capable of detecting Hypoxemia) and more. See video: https://www.youtube.com/watch?v=AmzxZb3WJi0
All devices described herein will have to go through FDA regulatory approvals and additional patents will have to be filed for IP protection. See video of our devices: https://vimeo.com/859865937/43efc178ad
About the Transaction:
Logiq will acquire EVIMATE through a share exchange and providing of working capital, issuing new Logiq shares for
CFO Adam Yang on the Acquisition:
"This union with EVIMATE propels us into the lucrative medical devices domain, enabling the development of groundbreaking treatments and enhancing our market presence," stated Adam Yang, CFO of Logiq.
Anticipated Outcomes:
Capital Raise: The combined entity plans to secure a significant capital infusion in line with the transaction.
Uplisting Goals: Logiq plans to transition from OTC Markets to a Nasdaq or NYSE listing by Q1 2025, enhancing its market presence and investor appeal.
Additional Acquisitions: Targeting six additional strategic acquisitions, which are currently in process, to provide a path to significant revenues by mid-2025.
New Direction for Logiq:
Founded in November 2004, Logiq has transitioned from e-commerce solutions to targeting the medical field, specifically cell and gene therapy, longevity, anti-aging, and rejuvenation. Post-acquisitions, Logiq will be managed by executives and R&D scientific staff with decades of experience.
Business Model:
Drug Development: Focusing on innovative therapies to address unmet medical needs.
Medical Devices/Remote Monitoring: Harnessing technology to enhance patient outcomes.
Rare Diseases: Exploring new frontiers in treatment for the most challenging conditions.
Strategic Partnerships: Collaborating with industry leaders to accelerate progress.
Sales & Marketing Support: Providing comprehensive backing to ensure success in competitive markets.
Human Resources Development: Cultivating a dynamic workforce.
Longevity Treatments:
Logiq embraces longevity medicine, utilizing advanced AI to decode the science of aging, offering treatments that add years to life and life to years.
Cell and Gene Therapy:
Logiq's commitment extends to revolutionary cell and gene therapies that modify or replace genetic material to combat diseases at their root, promising lasting cures.
Strategic Partnerships and Equity Stakes:
Logiq's strategic partnerships foster mutual growth and innovation, engaging with clients and organizations to:
Collaborate on Research: Enhance collective R&D capabilities.
Share Technological Resources: Utilize AI tools to improve efficiency and outcomes.
Acquire Stakes: Consider acquiring minority stakes in partners' infrastructure.
Offer Equity Stakes: Create symbiotic relationships driving forward health innovation.
About EVIMATE:
EVIMATE's cutting-edge suite of vital sign products leverage advanced AI technology to provide comprehensive monitoring and predictive analytics across key health metrics. The solution combines next-generation devices with a user-friendly app to ensure continuous, accurate monitoring of temperature, heart rate, ECG, blood pressure, oxygen levels, and glucose levels.
The transaction is slated for completion by October 7, 2024, subject to standard closing conditions.
About Logiq:
Logiq Inc., headquartered in the United States, revolutionizes e-commerce and digital customer acquisition by streamlining digital advertising. The company offers comprehensive, data-driven marketing solutions and software to engage customers across various channels.
Important Cautions Regarding Forward-Looking Statements:
This press release contains forward-looking statements and information, subject to the Safe Harbor created by Sections 27A of the Securities Act of 1933 and 21E of the Securities Exchange Act of 1934. These statements involve estimates, assumptions, and uncertainties that could cause actual results to differ materially from those expressed. No assurance can be given that these expectations will prove correct, and such forward-looking statements should not be unduly relied upon.
Media & Investor Contact:
+1.917.353.5099
brent@logiq.com
SOURCE: Logiq, Inc.
View the original press release on accesswire.com
FAQ
What is the value of Logiq's acquisition of EVIMATE?
What types of health metrics does EVIMATE's technology monitor?
Does EVIMATE offer any automotive health monitoring solutions?
What regulatory approvals are needed for EVIMATE's devices?
